Publisher's Synopsis
This series of annual volumes on biomedical policy identifies cutting-edge issues that arise from a rapidly growing array of new technologies. Volume II focuses on two substantive areas beset by novel power conflicts: decisions involving end-of-life technologies - physicians, patients, and public officials locked in new battles over whether and when life-extending technologies should be begun or ended, and rules governing medical experimentation - researchers, government officials, and patients vying to determine who will receive experimental medical treatment and what procedures should be instituted to protect the recipients.
